A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Conditions

Non-Hodgkin's Lymphoma

Phase I

What is the purpose of this trial?

This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-636, an oral Dihydroorotate Dehydrogenase (DHODH) inhibitor, in subjects with advanced lymphoma.

  • Trial with
    Agios Pharmaceuticals
  • Start Date
    03/23/2019
  • End Date
    02/21/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Laura Leary

  • Last Updated
    05/19/2019
  • Study HIC
    #2000024525